查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832353

脑肿瘤诊断和治疗市场（按治疗类型、诊断类型、最终用户和肿瘤类型划分）—2025-2032 年全球预测

Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, End User, Tumor Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到2032年脑瘤诊断和治疗市场规模将成长至31.1亿美元，复合年增长率为7.04%。

主要市场统计数据
基准年2024年 18亿美元
预计2025年 19.3亿美元
预测年份：2032年 31.1亿美元
复合年增长率（%） 7.04%

对不断变化的临床、技术和操作环境进行清晰而令人信服的介绍，重塑全球脑肿瘤诊断和治疗途径。

脑瘤的诊断和治疗正处于快速科学创新与复杂临床决策的交会点，需要临床医生、研究人员和医疗系统领导者的严谨指导。分子生物学、影像技术和治疗治疗方法的进步提升了诊断的准确性和治疗方法方案，但同时也带来了患者选择、手术流程、报销和监管协调等方面的全新复杂性。因此，相关人员必须平衡新治疗方法的前景与现实限制，例如设施的可及性、跨学科合作以及长期疗效的衡量。

在过去十年中，临床诊疗方案已从「一刀切」的策略转变为更个人化的方案，将分子诊断与先进的影像学和标靶治疗相结合。因此，第一线医疗越来越依赖整合的诊断途径，这些途径结合了切片检查技术、影像学方法和分子检测，以获得对肿瘤生物学的更深入的理解。这种演变对临床工作流程、实验室实践和跨学科培训有着直接的影响，为供应商和医疗系统重新思考其服务提供模式创造了机会。

展望未来，将诊断准确性转化为持续的治疗效益将取决于诊断、外科手术、全身性治疗和支持性护理等各环节的协调改进。积极投资跨职能能力（从混合手术室和立体定位平台到分子病理学和数据整合）的医疗系统将更有能力运用新证据并改善患者预后。本介绍涵盖转型变革、资费相关影响、细分考量、区域动态、竞争洞察以及为领导者在不断变化的市场环境中提供切实可行的建议。

全面检验诊断、治疗和数位融合创新，重新定义脑肿瘤治疗和临床决策的精准途径

在诊断、治疗和数据主导医疗服务整合发展的推动下，脑肿瘤生态系统正在经历变革。影像学已从解剖学描绘转向功能和分子表征，从而能够更早发现治疗反应和復发情况，并制定更精准的手术计划。同时，基因表现分析、次世代定序和基于PCR的检测，正在重新定义肿瘤的分类和预后，并在治疗方法选择方面发挥越来越重要的作用。

在治疗方面，分子标靶药物和免疫疗法正在改变治疗流程。标靶治疗，例如Bevacizumab、mTOR抑制剂和蛋白酪氨酸激酶抑制剂，为特定肿瘤亚型提供精准的、基于机制的治疗；而免疫疗法，例如嵌合抗原受体T细胞疗法、查核点抑制剂和癌症疫苗，则致力于实现持久的抗肿瘤免疫力。放射疗法创新涵盖体外照射、立体定位放射放射线手术和近距离放射治疗，可增强局部控制，同时降低继发性毒性。外科手术技术也不断进步，影像导引切除术和微创立体定位手术改善了最大切除范围和功能保留之间的平衡。

数位转型正在扩大这些临床创新。人工智慧和机器学习增强了影像解读能力，实现了分割自动化，并支援预后建模，从而缩短了诊断时间，并实现了更个人化的监测策略。临床和基因组数据的互通性支持了多学科肿瘤委员会，并加速了转化研究。总而言之，这些转变正在创造一个精准诊断和多学科护理融合以提供个人化治疗方法的格局——这也引发了关于公平获取、报销政策以及大规模实现这些效益所需的劳动力能力的紧迫问题。

对近期贸易政策调整和关税动态如何影响供应链、筹资策略以及脑癌治疗的临床应用进行批判性分析

贸易和关税政策的变化对临床供应链、研究采购和设备供应产生连锁反应，显着影响脑肿瘤治疗的发展。进口关税和监管要求的变化增加了采购先进成像硬体、立体定位设备和专用耗材的成本和复杂性，同时也影响了分子诊断和次世代定序仪工作流程中使用的试剂的供应和定价。这些下游压力可能会增加诊断实验室和影像中心的工作量，延迟资本升级，并限制在常规临床实践中采用新诊断方法的速度。

除了直接采购影响外，关税主导的转变可能会重组国内外供应商之间的伙伴关係，并促使製造商重新评估生产基地和供应链冗余。为此，医疗保健提供者和研发机构可能会优先考虑策略采购，延长库存前置作业时间，并实现供应商关係多元化，以降低供应风险。重要的是，关税引发的成本压力也可能影响与付款人的价格谈判，减缓资本密集型治疗平台的采用，并推动系统层面的决策，即在何处集中专科服务以实现规模经济。

对于研究网络和临床试验而言，生物材料、设备和临床实验套件跨境流动的变化可能会造成物流障碍，影响临床试验的启动和样本处理的时间表。因此，研究申办方和研究人员必须预见贸易相关的意外事件，并将其纳入研究规划和预算中。总体而言，关税动态是获取和创新的非临床决定因素，凸显了积极主动的供应链策略、政策参与和自适应采购模式的必要性，以保持改善脑肿瘤诊断和治疗的势头。

全面的细分驱动集成，主导治疗方式、诊断工作流程、最终用户和肿瘤亚型的细微差别，以指导策略优先排序

细分感知观点揭示了投资和营运重点，这将最有效地加速整个诊断和治疗途径中以患者为中心的结果。依治疗类型，有化疗、免疫疗法、放射线治疗、手术和标靶治疗。化疗包括联合治疗、亚硝脲和Temozolomide；免疫疗法包括 CAR T 细胞疗法、查核点抑制剂和疫苗；放射线治疗包括近距离放射治疗、体外放射线治疗和立体定位放射线手术。标靶治疗方案包括Bevacizumab、mTOR 抑制剂和蛋白酪氨酸激酶抑制剂，每种药物的作用机制不同，需要协调一致的诊断策略和结果测量。

诊断细分进一步明确了临床工作流程和实验室需求。根据诊断类型，诊断流程包括切片检查、影像学和分子诊断。切片检查技术涵盖从开放性切片检查到立体定位切片检查；影像学包括电脑断层扫描、磁振造影造影、正子断层扫描和超音波；分子诊断则结合了基因表现分析、次世代定序和基于PCR的检测，为治疗方法选择和预后预测提供分子背景资讯。这些诊断方式与治疗选择和监测范式密切相关，并为多学科护理路径的设计提供参考。

最终用户细分有助于了解服务的交付地点和容量限制。根据最终用户，医疗服务由诊断中心、医院、研究机构和专科诊所提供，每个机构的基础设施、人员配备模式和报销介面均不相同。基于肿瘤类型的细分凸显了临床异质性。基于肿瘤类型的主要分类包括神经胶质瘤、髓母细胞瘤、脑膜瘤和脑下垂体瘤。神经胶质瘤包括星状细胞瘤、胶质母细胞瘤和寡树突胶质瘤，而脑下垂体瘤的分类包括颅咽瘤和脑下垂体腺瘤。根据肿瘤亚型量身订做治疗方法和诊断强度对于优化结果和资源分配至关重要，这凸显了从诊断到纵向监测的综合护理途径的必要性。

影响全球卫生系统取得和实施的区域采用模式、基础设施动态和政策背景的细緻评估

区域动态对医疗体系中诊断创新和治疗方式的采用、扩展和报销方式有重大影响。美洲的临床生态系统涵盖大型综合学术医疗中心和社区医院，为技术采用、集中式专科服务和多机构合作创造了多样化的途径。该地区的筹资策略和报销模式决定了先进成像、立体定位平台和分子检测融入标准实践的速度。欧洲、中东和非洲是一个多元化的地区，法律规范、医疗体系资金筹措和基础设施方面的差异导致了不同的采用曲线。虽然高容量中心分散在各个地区，但在某些地区，获得复杂诊断和专科程序的机会仍然有限，这促使人们依赖转诊网路和区域卓越中心。

受国际临床研究和跨境合作参与度提升的推动，亚太地区临床基础设施以及诊断剂和医疗设备的国内生产能力正在快速扩张。在许多亚太市场，公共对三级医疗保健的投资正与私部门的参与度不断提升相结合，加速了技术应用。在整个地区，临床和基因组数据互通性网络、劳动力发展和远端医疗的增强，正在成为扩大专科医生就诊管道的推动因素。了解区域差异对于制定实施策略、协调商业性参与以及建立兼顾当地监管、经济和临床现实的合作至关重要。

深入审查竞争动态、伙伴关係策略和创新重点领域，这将决定哪些公司将推动临床应用和服务发展

脑肿瘤诊断和治疗生态系统的竞争态势反映了老牌生物医学公司、新兴生物技术创新者、专业设备製造商和诊断实验室的整合。大型医疗设备和製药公司继续利用其规模、监管经验和分销网络，支援诊断影像平台、立体定位系统和已通过核准疗法的广泛临床部署。同时，规模较小的专业公司和学术衍生公司正在推动精准放射治疗规划、分子检测开发和新型免疫疗法等利基领域的创新，并经常与大型公司合作，推进后期开发和商业化。

随着治疗决策越来越依赖生物标记和影像资讯的整合，诊断服务提供者和治疗开发商之间的策略合作变得越来越重要。将实验室开发的检测方法、次世代定序和临床试验网络结合起来的伙伴关係，有助于患者分层，并加速转化研发流程。智慧财产权策略、监管途径导航和真实世界证据生成是致力于持续临床应用的公司的关键差异化因素。此外，委外研发机构、专业服务供应商和区域代理商在临床试验物流和复杂技术的本地化部署方面发挥关键作用。

相关人员在评估竞争对手活动时，应专注于积极投资的领域，例如分子诊断平台、人工智慧影像解决方案、立体定位放射放射线手术系统以及细胞疗法生产能力。拥有强大临床证据基础、清晰的报销策略和可扩展服务模式的公司将最有能力将创新转化为广泛的临床效用。最终，成功取决于商业策略是否与临床工作流程、付款人要求以及神经肿瘤科设施的营运现状一致。

领导者可以采取一系列切实可行的优先策略行动，以确保诊断准确性和治疗方法创新转化为公平的临床影响

行业领导者必须采取积极主动的策略，将技术能力转化为持续的临床价值和公平的可及性。首先，投资于整合诊疗途径，将分子分析、高阶影像和多学科临床决策融入无缝衔接的工作流程。其次，透过多元化专用耗材、试剂和资本设备的供应商关係，并制定紧急时应对计画以因应政策变化或物流限製造成的采购中断，从而增强供应链的韧性。

第三，我们将与学术中心、社区医疗保健提供者和产业建立合作伙伴关係，以扩大患者获得专科诊断和新型疗法的管道，并进行更大规模、更具代表性的临床研究。第四，我们将设计临床和现实世界研究，以证明比较有效性、以患者为中心的结果以及与报销决策相关的成本影响，从而使证据生成与付款人的期望保持一致。第五，我们将投资于劳动力发展和跨学科培训，使临床医生、病理学家、放射科医生和实验室工作人员能够操作复杂的诊断演算法，并安全有效地提供多学科护理。

最后，采用考虑公平和经济的以患者为中心的商业化策略，例如分层交付模式、远端医疗支援网络和集中高复杂度护理的区域卓越中心，将使相关人员能够将科学进步转化为可扩展的临床效益，同时管理营运风险并加强整个卫生系统的相关人员合作。

我们的分析基于一种透明的、基于临床的方法，结合了主要专家访谈、系统文献综合和多源检验

本分析背后的调查方法结合了多方面的定性和定量分析技术，以确保研究结果全面且检验。主要研究包括对临床专家、实验室主任、医院采购负责人和行业高管进行结构化访谈，以获取关于诊断工作流程、治疗决策和运营限制的第一手观点。次要研究则包括对同侪审查文献、临床指南更新、监管沟通和公共卫生政策文件的系统性回顾，以揭示临床实践和技术的发展轨迹。

资料合成采用三角测量技术，将主要访谈结果与已发表的证据和产业揭露资讯进行比对。与领域专家进行的检验轮次确保对技术能力、监管途径和营运可行性的解读能够反映当前的实践模式。本研究指南伦理考量，包括保护访谈期间共用的机密资讯以及对机密业务事项进行去身分化处理。调查方法的局限性包括不同地区数据粒度的差异以及新治疗方法的依证的不断演变。

总体而言，该调查方法优先考虑透明度、交叉检验和临床有效性，所产生的分析结果可支持脑肿瘤诊断和治疗领域的营运决策、策略规划和进一步的研究合作。

简洁而明确的结论，结合了实现诊断进步、治疗方法多样化和改善患者结果所需的系统性要求。

本执行摘要概述了诊断创新、治疗多样化和系统性因素如何塑造现代脑肿瘤治疗。分子诊断和影像技术的进步提高了诊断准确性并为治疗分层提供了信息，而标靶治疗、免疫治疗和放射治疗的改进则拓展了治疗选择。虽然这些发展为改善疗效提供了机会，但安全有效的治疗需要在基础设施、人才培养和证据生成方面进行协同投资。

贸易政策动态和区域基础设施差异等外部因素会影响实施的速度和公平性，进而影响采购、研究物流以及获得先进医疗服务的管道。竞争动态凸显，那些整合诊断和治疗价值提案、展示临床和经济价值并建立可扩展服务交付模式的营业单位将取得成功。切实可行的建议主要包括：建立综合路径、增强供应链韧性、培育协作网络、使证据生成与付款人需求相一致，以及致力于劳动力和医疗服务可及性计划。

最后，实现改善脑肿瘤治疗的愿景需要临床医生、卫生系统、产业和政策制定者的共同行动。积极主动地将技术能力与营运准备和公平的交付模式相结合的相关人员，将最有能力将创新转化为有意义的患者利益和永续的系统影响。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合人工智慧驱动的放射组学分析平台，实现准确的肿瘤表征和治疗计划
  • 扩大血液液态生物检体，以早期发现和监测胶质母细胞瘤进展
  • 采用术中萤光引导成像技术改善肿瘤切除边缘
  • 针对突变型 EGFRvIII 和其他新型胶质瘤抗原的 CAR T 细胞疗法的开发
  • 神经肿瘤学中下一代质子治疗系统的监管核准和商业化策略
  • 远距远端医疗平台在脑肿瘤治疗的应用

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章脑肿瘤诊断与治疗市场（依治疗类型）

  • 化疗
    • 联合治疗
    • 亚硝脲类
    • Temozolomide
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
    • 疫苗
  • 放射线治疗
    • 近距离放射治疗
    • 体外放射治疗
    • 立体定位放射线手术
  • 外科手术
  • 标靶治疗
    • Bevacizumab
    • Mtor抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章脑肿瘤诊断与治疗市场（依诊断类型）

  • 切片检查
    • 开放切片检查
    • 立体定位切片检查
  • 影像学
    • 电脑断层扫描
    • 磁振造影
    • 正子断层扫描
    • 超音波
  • 分子诊断
    • 基因表现
    • 次世代定序
    • 基于PCR的检测

第 10 章脑肿瘤诊断与治疗市场（依最终使用者）

  • 诊断中心
  • 医院
  • 研究机构
  • 专科诊所

第11章脑肿瘤诊断与治疗市场（依肿瘤类型）

  • 胶质瘤
    • 星状细胞瘤
    • 神经胶母细胞瘤
    • 寡树突胶质瘤
  • 髓母细胞瘤
  • 脑膜瘤
  • 脑下垂体瘤
    • 颅咽瘤
    • 脑下垂体腺瘤

第十二章脑肿瘤诊断与治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章脑肿瘤诊断与治疗市场（按群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国脑瘤诊断与治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Siemens Healthineers AG
    • GE Healthcare LLC
    • Koninklijke Philips NV
    • Elekta AB
    • Varian Medical Systems, Inc.
    • Accuray Incorporated
    • Roche Holding AG
    • Novartis AG
    • Merck & Co., Inc.
    • Novocure Limited
Product Code: MRR-437D459585B5

The Brain Tumor Diagnosis & Treatment Market is projected to grow by USD 3.11 billion at a CAGR of 7.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.80 billion
Estimated Year [2025] USD 1.93 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 7.04%

A clear and compelling introduction to the evolving clinical, technological, and operational landscape reshaping brain tumor diagnosis and treatment pathways globally

Brain tumor diagnosis and treatment sit at the intersection of rapid scientific innovation and complex clinical decision-making, demanding rigorous navigation by clinicians, researchers, and health system leaders. Advances in molecular biology, imaging technology, and therapeutic modalities have expanded diagnostic precision and therapeutic options, yet they have also introduced new layers of complexity around patient selection, procedural workflows, reimbursement, and regulatory alignment. Consequently, stakeholders must reconcile the promise of novel interventions with real-world constraints such as equipment access, interdisciplinary coordination, and long-term outcome measurement.

Over the past decade, the clinical narrative has shifted from one-size-fits-all strategies toward more personalized approaches that integrate molecular insights with advanced imaging and targeted therapies. As a result, frontline practice increasingly relies on integrated diagnostic pathways that combine biopsy techniques, imaging modalities, and molecular assays to produce a nuanced understanding of tumor biology. This evolution has immediate implications for clinical workflows, laboratory operations, and cross-disciplinary training, and it creates opportunities for vendors and health systems to reimagine service delivery models.

Looking ahead, the ability to translate diagnostic precision into durable therapeutic benefit will hinge on coordinated improvements across diagnostics, surgery, systemic therapies, and supportive care. Health systems that proactively invest in cross-functional capabilities-ranging from hybrid operating suites and stereotactic platforms to molecular pathology and data integration-will be better positioned to operationalize emerging evidence and improve patient outcomes. This introduction frames the subsequent sections, which explore transformational shifts, tariff-related impacts, segmentation insights, regional dynamics, competitive considerations, and actionable recommendations for leaders navigating this evolving landscape.

An in-depth examination of converging diagnostic, therapeutic, and digital innovations that are redefining precision pathways for brain tumor care and clinical decision-making

The brain tumor ecosystem is undergoing transformative shifts driven by converging advances in diagnostics, therapeutics, and data-driven care delivery. Imaging has moved beyond anatomical depiction to functional and molecular characterization, enabling earlier detection of treatment response and recurrence and permitting more nuanced surgical planning. Parallel advances in molecular diagnostics, including gene expression profiling, next generation sequencing, and PCR-based assays, have redefined tumor classification and prognostication, and they increasingly inform therapeutic selection.

On the therapeutic front, targeted agents and immunotherapies are changing the treatment algorithm. Targeted Therapy options such as bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors provide mechanistic precision for select tumor subtypes, while immunotherapy approaches including CAR T-cell therapy, checkpoint inhibitors, and cancer vaccines are extending lines of inquiry into durable anti-tumor immunity. Radiotherapy innovation, spanning external beam modalities, stereotactic radiosurgery, and brachytherapy, is enhancing focal control with reduced collateral toxicity. Surgical technology has likewise advanced, with image-guided resection and minimally invasive stereotactic approaches improving the balance between maximal resection and functional preservation.

Digital transformation is amplifying these clinical innovations. Artificial intelligence and machine learning augment imaging interpretation, automate segmentation, and support prognostic modeling, thereby shortening diagnostic timelines and enabling more personalized surveillance strategies. Interoperability of clinical and genomic data supports multidisciplinary tumor boards and accelerates translational research. Taken together, these shifts are creating a landscape in which precision diagnostics and multimodal treatment converge to offer individualized pathways, while simultaneously raising pressing questions about equitable access, reimbursement policy, and the workforce competencies required to realize these benefits at scale.

A rigorous analysis of how recent trade policy adjustments and tariff dynamics are influencing supply chains, procurement strategies, and clinical adoption in brain tumor care

Policy shifts in trade and tariffs can produce ripple effects across clinical supply chains, research procurement, and device availability that materially influence the delivery of brain tumor care. Changes to import duties and regulatory requirements raise the cost and complexity of sourcing advanced imaging hardware, stereotactic equipment, and specialized disposables, while also affecting the availability and pricing of reagents used in molecular diagnostics and next generation sequencing workflows. These downstream pressures can increase operational burden for diagnostic laboratories and imaging centers, delay capital upgrades, and constrain the pace at which new diagnostic modalities are adopted in routine clinical practice.

Beyond direct procurement impacts, tariff-driven shifts can reshape partnerships between domestic and international suppliers, prompting manufacturers to reevaluate production footprints and supply chain redundancy. In response, providers and research institutions may prioritize strategic procurement, develop longer inventory lead times, and diversify vendor relationships to mitigate supply risk. Importantly, tariff-induced cost pressures can also influence pricing negotiations with payers, slow adoption of capital-intensive therapeutic platforms, and prompt system-level decisions around where specialized services are centralized to achieve economies of scale.

For research networks and clinical trials, changes to cross-border movement of biological materials, instrumentation, and diagnostic kits can introduce logistical hurdles that affect trial initiation and sample processing timelines. Consequently, research sponsors and clinical investigators must anticipate and incorporate trade-related contingencies into study design and budgeting. In the aggregate, tariff dynamics act as a non-clinical determinant of access and innovation, underscoring the need for proactive supply chain strategies, policy engagement, and adaptive procurement models to preserve the momentum of improvements in brain tumor diagnosis and treatment.

A comprehensive segmentation-driven synthesis connecting treatment modalities, diagnostic workflows, end users, and tumor subtype nuances to guide strategic prioritization

A segmentation-aware perspective illuminates where investment and operational focus will most effectively accelerate patient-centered outcomes across diagnostic and therapeutic pathways. Based on Treatment Type, the clinical landscape encompasses Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy; within these categories, Chemotherapy pathways include combination therapies, nitrosoureas, and temozolomide, while Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccines, and Radiotherapy comprises brachytherapy, external beam radiotherapy, and stereotactic radiosurgery. Targeted Therapy options span bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors, each offering distinct mechanisms that require aligned diagnostic strategies and outcome measurement.

Diagnostic segmentation further clarifies clinical workflows and laboratory needs. Based on Diagnosis Type, the diagnostic continuum includes biopsy, imaging, and molecular diagnostics; biopsy procedures range from open biopsy to stereotactic biopsy, imaging modalities include computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, and molecular diagnostics incorporate gene expression profiling, next generation sequencing, and PCR-based assays to provide molecular context for therapeutic choice and prognostication. These diagnostic modalities interact closely with treatment selection and surveillance paradigms and inform the design of multidisciplinary care pathways.

End user segmentation highlights where services are delivered and where capacity constraints may emerge. Based on End User, care is provided across diagnostic centers, hospitals, research institutes, and specialty clinics, each with distinct infrastructure, staffing models, and reimbursement interfaces. Tumor type segmentation brings clinical heterogeneity into focus. Based on Tumor Type, the principal categories include glioma, medulloblastoma, meningioma, and pituitary tumor; glioma includes astrocytoma, glioblastoma, and oligodendroglioma, while pituitary tumor distinctions include craniopharyngioma and pituitary adenoma. Aligning therapeutic modalities and diagnostic intensity with tumor subtype is essential for optimizing outcomes and resource allocation, and it emphasizes the need for integrated care pathways that span diagnosis through long-term surveillance.

A nuanced assessment of regional adoption patterns, infrastructure dynamics, and policy contexts shaping access and implementation across global health systems

Regional dynamics exert a profound influence on how diagnostic innovations and therapeutic modalities are adopted, scaled, and reimbursed across health systems. In the Americas, clinical ecosystems vary from large integrated academic medical centers to community hospitals, producing diverse pathways for technology adoption, centralized specialty services, and multisite research collaboration; procurement strategies and reimbursement models in this region shape the pace at which advanced imaging, stereotactic platforms, and molecular testing are integrated into standard practice. Europe, Middle East & Africa presents a heterogeneous picture in which regulatory frameworks, health system financing, and infrastructure disparities create differentiated adoption curves; pockets of high-capacity centers coexist with regions where access to complex diagnostics and specialty surgery remains limited, prompting a reliance on referral networks and regional centers of excellence.

Asia-Pacific demonstrates rapid capacity expansion in both clinical infrastructure and domestic manufacturing of diagnostic reagents and medical devices, accompanied by growing participation in international clinical research and cross-border collaboration. The convergence of public investment in tertiary healthcare and increased private sector involvement in many Asia-Pacific markets accelerates the diffusion of technology, while also creating varied payer landscapes that affect affordability and access. Across all regions, interoperability of clinical and genomic data, workforce training, and telemedicine-enhanced networks act as enablers for expanding access to specialist expertise. Understanding regional nuances is critical for tailoring implementation strategies, aligning commercial engagement, and structuring collaborative research that accounts for local regulatory, economic, and clinical realities.

An incisive review of competitive dynamics, partnership strategies, and innovation focus areas that determine which companies will drive clinical adoption and service evolution

Competitive dynamics in the brain tumor diagnosis and treatment ecosystem reflect a blend of established biomedical firms, emerging biotechnology innovators, specialized device manufacturers, and diagnostic laboratories. Large medical device and pharmaceutical companies continue to leverage scale, regulatory experience, and distribution networks to support wide clinical deployment of imaging platforms, stereotactic systems, and approved therapeutics. At the same time, smaller specialized firms and academic spin-outs drive innovation in niche areas such as precision radiotherapy planning, molecular assay development, and novel immunotherapeutic constructs, often partnering with larger organizations to progress late-stage development and commercialization.

Strategic collaborations between diagnostics providers and therapeutic developers are becoming increasingly important as treatment decisions rely on integrated biomarker and imaging information. Partnerships that bridge laboratory-developed tests, next generation sequencing, and clinical trial networks facilitate patient stratification and accelerate translational pipelines. Intellectual property strategy, regulatory pathway navigation, and real-world evidence generation are key differentiators for companies that seek durable clinical adoption. Moreover, contract research organizations, specialty service providers, and regional distributors play a pivotal role in enabling clinical trial logistics and localized deployment of complex technologies.

For stakeholders evaluating competitor behavior, attention should focus on areas of active investment such as molecular diagnostics platforms, AI-enabled imaging solutions, stereotactic radiosurgery systems, and cell therapy manufacturing capacity. Companies that combine robust clinical evidence generation with clear reimbursement strategies and scalable service models are best positioned to transform innovations into widespread clinical utility. Ultimately, success hinges on aligning commercial strategy with clinical workflows, payer requirements, and the operational realities of centers delivering neuro-oncology care.

A set of practical and prioritized strategic actions that leaders can implement to ensure diagnostic precision and therapeutic innovation translate into equitable clinical impact

Industry leaders must adopt proactive strategies to translate technological potential into consistent clinical value and equitable access. First, invest in integrated diagnostic-to-therapy pathways that bring molecular profiling, advanced imaging, and multidisciplinary clinical decision-making into seamless workflows; prioritizing interoperability and data standards will streamline case review and accelerate therapy selection. Second, strengthen supply chain resilience by diversifying vendor relationships for specialized consumables, reagents, and capital equipment, and by developing contingency plans that address procurement disruptions caused by policy shifts or logistical constraints.

Third, forge collaborative partnerships across academic centers, community providers, and industry to broaden patient access to specialized diagnostics and novel therapies, while also enabling larger, more representative clinical studies. Fourth, align evidence generation with payer expectations by designing clinical and real-world studies that demonstrate comparative effectiveness, patient-centered outcomes, and cost implications relevant to reimbursement decisions. Fifth, invest in workforce development and cross-disciplinary training to ensure clinicians, pathologists, radiologists, and laboratory staff can operationalize complex diagnostic algorithms and deliver multimodal treatments safely and effectively.

Finally, adopt a patient-centric commercialization strategy that considers equity and affordability, including tiered delivery models, telemedicine-enabled networks, and regional centers of excellence that concentrate high-complexity care. By implementing these actions, leaders can convert scientific advances into scalable clinical benefits while managing operational risk and strengthening stakeholder alignment across health systems.

A transparent and clinically grounded methodology combining primary expert interviews, systematic literature synthesis, and multi-source validation to underpin the analysis

The research approach underpinning this analysis combined multifaceted qualitative and quantitative methods to ensure comprehensive and validated findings. Primary research comprised structured interviews with clinical specialists, laboratory directors, hospital procurement leaders, and industry executives to capture firsthand perspectives on diagnostic workflows, therapeutic decision-making, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, clinical guideline updates, regulatory communications, and public health policy documents to contextualize clinical practice and technology trajectories.

Data synthesis employed triangulation techniques to reconcile insights from primary interviews with published evidence and industry disclosures. Validation rounds with subject matter experts ensured that interpretations of technological capability, regulatory pathways, and operational feasibility reflected current practice patterns. Ethical considerations guided the research, including protection of confidential information shared during interviews and de-identification of sensitive operational details. Limitations of the methodology included variability in regional data granularity and evolving evidence bases for emerging therapies; where appropriate, findings emphasize directional insights and implementation considerations rather than definitive long-term projections.

Overall, the methodology prioritized transparency, cross-validation, and clinical relevance to produce an analysis that supports operational decision-making, strategic planning, and further research collaboration within the brain tumor diagnosis and treatment domain.

A concise and decisive conclusion tying together diagnostic advances, therapeutic diversification, and systemic imperatives required to realize improved patient outcomes

This executive summary synthesizes how diagnostic innovation, therapeutic diversification, and systemic factors jointly shape contemporary brain tumor care. Advances in molecular diagnostics and imaging have enhanced diagnostic precision and informed treatment stratification, while targeted therapies, immunotherapies, and radiotherapy refinements are expanding therapeutic options. These developments create opportunities for improved outcomes but also necessitate coordinated investments in infrastructure, workforce training, and evidence generation to ensure safe and effective adoption.

External forces such as trade policy dynamics and regional infrastructure disparities influence the speed and equity of implementation, affecting procurement, research logistics, and access to advanced care. Competitive dynamics reveal that successful entities will be those that integrate diagnostic and therapeutic value propositions, demonstrate clinical and economic value, and build scalable service delivery models. Actionable recommendations center on creating integrated pathways, strengthening supply chain resilience, fostering collaborative networks, aligning evidence generation with payer needs, and committing to workforce and access initiatives.

In closing, realizing the promise of improved brain tumor care will require coordinated action across clinicians, health systems, industry, and policymakers. Stakeholders who proactively align technological capability with operational readiness and equitable delivery models will be best positioned to convert innovation into meaningful patient benefit and sustainable system impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven radiomics analysis platforms for precise tumor characterization and treatment planning
  • 5.2. Expansion of blood-based liquid biopsy assays for early detection and monitoring of glioblastoma progression
  • 5.3. Adoption of intraoperative fluorescence-guided imaging techniques to improve tumor resection margins
  • 5.4. Development of CAR T cell therapies targeting mutant EGFRvIII and other novel glioma antigens
  • 5.5. Regulatory approvals and commercialization strategies for next-generation proton therapy systems in neuro-oncology
  • 5.6. Implementation of telemedicine platforms for remote multidisciplinary tumor board consultations in brain cancer care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapies
    • 8.1.2. Nitrosoureas
    • 8.1.3. Temozolomide
  • 8.2. Immunotherapy
    • 8.2.1. Car T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccines
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam Radiotherapy
    • 8.3.3. Stereotactic Radiosurgery
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Bevacizumab
    • 8.5.2. Mtor Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Treatment Market, by Diagnosis Type

  • 9.1. Biopsy
    • 9.1.1. Open Biopsy
    • 9.1.2. Stereotactic Biopsy
  • 9.2. Imaging
    • 9.2.1. Computed Tomography
    • 9.2.2. Magnetic Resonance Imaging
    • 9.2.3. Positron Emission Tomography
    • 9.2.4. Ultrasound
  • 9.3. Molecular Diagnostics
    • 9.3.1. Gene Expression Profiling
    • 9.3.2. Next Generation Sequencing
    • 9.3.3. Pcr-Based Assays

10. Brain Tumor Diagnosis & Treatment Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. Brain Tumor Diagnosis & Treatment Market, by Tumor Type

  • 11.1. Glioma
    • 11.1.1. Astrocytoma
    • 11.1.2. Glioblastoma
    • 11.1.3. Oligodendroglioma
  • 11.2. Medulloblastoma
  • 11.3. Meningioma
  • 11.4. Pituitary Tumor
    • 11.4.1. Craniopharyngioma
    • 11.4.2. Pituitary Adenoma

12. Brain Tumor Diagnosis & Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Tumor Diagnosis & Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Tumor Diagnosis & Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. GE Healthcare LLC
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Elekta AB
    • 15.3.5. Varian Medical Systems, Inc.
    • 15.3.6. Accuray Incorporated
    • 15.3.7. Roche Holding AG
    • 15.3.8. Novartis AG
    • 15.3.9. Merck & Co., Inc.
    • 15.3.10. Novocure Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY RE